{"id":23476,"date":"2025-04-13T17:39:49","date_gmt":"2025-04-13T17:39:49","guid":{"rendered":"https:\/\/researchchemicallab.eu\/?post_type=product&p=23476"},"modified":"2026-02-03T11:10:00","modified_gmt":"2026-02-03T11:10:00","slug":"4-h-mpt-fumarat","status":"publish","type":"product","link":"https:\/\/researchchemicallab.eu\/is\/bud\/4-klukkustundir-a-minutu\/4-h-mpt-fumarat\/","title":{"rendered":"4-HO-MPT f\u00famarat"},"content":{"rendered":"

4-HO-MPT f\u00famarat \u2013 H\u00e1g\u00e6\u00f0a ranns\u00f3knarefni fyrir framhaldsn\u00e1m<\/strong><\/h1>\n

V\u00f6ruheiti:<\/strong> 4-HO-MPT f\u00famarat
\nFullt nafn:<\/strong> 4-h\u00fddrox\u00fd-N-met\u00fdl-N-pr\u00f3p\u00fdltryptam\u00edn f\u00famarat
\nEfnaflokkur:<\/strong> Tryptam\u00edn
\nSameindaform\u00fala:<\/strong> C14H20N2O \u00b7 C4H4O4
\nHreinleiki:<\/strong> \u226598% (greind me\u00f0 HPLC)
\nL\u00edkamlegt form:<\/strong> F\u00ednt hv\u00edtt kristalla\u00f0 duft
\nCAS-n\u00famer:<\/strong> Ekki opinberlega skr\u00e1\u00f0 (ranns\u00f3knarefni)
\nEing\u00f6ngu \u00e6tla\u00f0 fyrir:<\/strong> Ranns\u00f3knir og notkun \u00e1 ranns\u00f3knarstofum<\/p>\n

\n

L\u00fdsing<\/strong><\/h2>\n

4-HO-MPT f\u00famarat er sjaldg\u00e6ft tryptam\u00edn efnasamband sem hefur \u00e1hrif \u00e1 ge\u00f0r\u00e6na virkni og byggingarlega hli\u00f0st\u00e6\u00f0a psilocin og 4-HO-MiPT. \u00deetta efni er oft nota\u00f0 \u00ed tilraunakenndum lyfjafr\u00e6\u00f0ilegum ranns\u00f3knum vegna einstakrar bindingar \u00feess vi\u00f0 ser\u00f3t\u00f3n\u00ednvi\u00f0taka, s\u00e9rstaklega 5-HT2A.<\/p>\n

Vegna l\u00edkingar vi\u00f0 n\u00e1tt\u00faruleg efnasamb\u00f6nd eins og psilocyn (sem finnst \u00ed psilocyb\u00edn sveppum), er 4-HO-MPT \u00e1hugavert fyrir v\u00edsindamenn sem vilja greina byggingarbreytingar innan tryptam\u00ednfj\u00f6lskyldunnar.<\/p>\n

\n

Notkunartilvik og notkunartilvik (eing\u00f6ngu ranns\u00f3knarstofa)<\/strong><\/h2>\n
    \n
  • Taugalyfjafr\u00e6\u00f0ilegar ranns\u00f3knir:<\/strong> Mat \u00e1 ser\u00f3t\u00f3n\u00ednvirkni og bindingars\u00e6kni.<\/li>\n
  • Mannvirkjak\u00f6nnun (SAR):<\/strong> Samanbur\u00f0argreining \u00e1 milli 4-HO-MiPT, 4-HO-DMT og skyldra aflei\u00f0a.<\/li>\n
  • Ranns\u00f3knir \u00e1 bindingu vi\u00f0taka:<\/strong> Virkni sameindarinnar \u00e1 mismunandi ser\u00f3t\u00f3n\u00ednvi\u00f0taka.<\/li>\n
  • Me\u00f0vitundarranns\u00f3knir (fr\u00e6\u00f0ilegar\/tilraunal\u00edk\u00f6n):<\/strong> L\u00edkanager\u00f0 breystra \u00e1standa \u00ed d\u00fdral\u00edk\u00f6num (EKKI til manneldis).<\/li>\n<\/ul>\n
    \n

    \u00c1vinningur af 4-HO-MPT f\u00famarati \u00ed ranns\u00f3knum<\/strong><\/h2>\n

    \u2714 Einst\u00f6k efnafr\u00e6\u00f0ileg uppbygging<\/strong> innan 4-HO ser\u00edunnar
    \n\u2714 Mikil hreinleiki<\/strong> tryggt (\u226598%)
    \n\u2714 Lengri st\u00f6\u00f0ugleiki<\/strong> \u00ed f\u00famaratformi samanbori\u00f0 vi\u00f0 frj\u00e1lsan basa
    \n\u2714 Hentar fyrir eigindleg og megindleg greining<\/strong><\/p>\n

    \n

    \u00d3kostir \/ \u00c1h\u00e6tta<\/strong><\/h2>\n

    \u2716 Ekki hentugt til manneldis<\/strong>
    \n\u2716 Takm\u00f6rku\u00f0 g\u00f6gn tilt\u00e6k<\/strong>, sem getur gert t\u00falkun ni\u00f0ursta\u00f0na fl\u00f3kna
    \n\u2716 \u00d3vissa \u00ed lagalegum m\u00e1lum<\/strong> \u2013 Sta\u00f0a er mismunandi eftir l\u00f6ndum
    \n\u2716 M\u00f6gulegt hr\u00f6\u00f0 ni\u00f0urbrot vi\u00f0 \u00fatsetningu fyrir lofti e\u00f0a raka<\/strong> \u00e1n vi\u00f0eigandi geymslu<\/p>\n

    \n

    Lei\u00f0beiningar um notkun (ranns\u00f3knarstofua\u00f0fer\u00f0)<\/strong><\/h2>\n
      \n
    1. Geymsla:<\/strong> Geymi\u00f0 \u00ed loft\u00fe\u00e9ttu \u00edl\u00e1ti \u00e1 k\u00f6ldum, \u00feurrum og dimmum sta\u00f0 (helst -20\u00b0C).<\/li>\n
    2. Leysi\u00f0 upp:<\/strong> Leysanlegt \u00ed etan\u00f3li, DMSO e\u00f0a \u00f6\u00f0rum hentugum leysum til greiningar \u00e1 ranns\u00f3knarstofu.<\/li>\n
    3. Skammtar \u00ed ranns\u00f3knum:<\/strong> Byrji\u00f0 me\u00f0 m\u00edkr\u00f3gr\u00f6mm kvar\u00f0a (t.d. 100\u2013500 \u00b5g) fyrir in vitro pr\u00f3fanir.<\/li>\n
    4. Greiningara\u00f0fer\u00f0ir:<\/strong> LC-MS, HPLC, NMR f\u00e1anleg ef \u00f3ska\u00f0 er eftir ranns\u00f3knarstofusk\u00fdrslu.<\/li>\n<\/ol>\n
      \n

      Ranns\u00f3knarstofugreining (samantekt)<\/strong><\/h2>\n
        \n
      • Ni\u00f0ursta\u00f0a HPLC:<\/strong> 98,7% hreinleiki<\/li>\n
      • NMR litr\u00f3f:<\/strong> Samr\u00e6md sta\u00f0festing \u00e1 bur\u00f0arvirki<\/li>\n
      • Br\u00e6\u00f0slumarksgreining:<\/strong> 124\u2013126\u00b0C<\/li>\n
      • Geymslupr\u00f3f:<\/strong> Engin markt\u00e6k ni\u00f0urbrot eftir 30 daga vi\u00f0 -20\u00b0C<\/li>\n<\/ul>\n

        \u00cdtarleg ranns\u00f3knarsk\u00fdrsla er f\u00e1anleg ef \u00f3ska\u00f0 er.<\/em><\/p>\n

        \n

        Algengar spurningar (FAQ)<\/strong><\/h2>\n

        \u2753 Er 4-HO-MPT l\u00f6glegt \u00ed m\u00ednu landi?<\/em><\/h3>\n

        L\u00f6gleg sta\u00f0a er mismunandi eftir l\u00f6gsagnarumd\u00e6mum. Athugi\u00f0 alltaf gildandi l\u00f6g \u00e1\u00f0ur en \u00fei\u00f0 kaupi\u00f0 og noti\u00f0.<\/p>\n

        \u2753 Getur \u00feessi vara veri\u00f0 notu\u00f0 af m\u00f6nnum e\u00f0a d\u00fdrum?<\/em><\/h3>\n

        Nr. 4-HO-MPT f\u00famarat er eing\u00f6ngu \u00e6tla\u00f0 til notkunar ranns\u00f3knar- og greiningartilgangi<\/strong>.<\/p>\n

        \u2753 Hversu lengi helst \u00fea\u00f0 st\u00f6\u00f0ugt?<\/em><\/h3>\n

        \u00deegar varan er geymd r\u00e9tt (\u00feurr, dimm, loft\u00fe\u00e9tt) helst h\u00fan endingarg\u00f3\u00f0 \u00ed a\u00f0 minnsta kosti 12 m\u00e1nu\u00f0i.<\/p>\n

        \u2753 Hva\u00f0 gerir \u00feetta efnasamband \u00e1hugavert samanbori\u00f0 vi\u00f0 \u00f6nnur 4-HO tryptam\u00edn?<\/em><\/h3>\n

        N-met\u00fdl-N-pr\u00f3p\u00fdl uppbyggingin veitir einstaka lyfjafr\u00e6\u00f0ilega eiginleika sem a\u00f0greinir hana fr\u00e1 skyldum efnum eins og 4-HO-DMT e\u00f0a 4-HO-MiPT.<\/p>\n

        \n

        M\u00e6lt me\u00f0 fyrir<\/strong><\/h2>\n

        \ud83d\udd2c H\u00e1sk\u00f3lar og ranns\u00f3knarstofnanir
        \n\ud83e\uddea Lyfjafr\u00e6\u00f0ilegar ranns\u00f3knarstofur
        \n\ud83e\uddec Taugaefnafr\u00e6\u00f0ilegar ranns\u00f3knir
        \n\ud83d\udcca SAR greiningarverkefni<\/p>\n

        \n

        Athugi\u00f0:<\/strong> 4-HO-MPT f\u00famarat er ekki matv\u00e6li, lyf e\u00f0a f\u00e6\u00f0ub\u00f3tarefni. \u00dea\u00f0 er eing\u00f6ngu \u00e6tla\u00f0 til notkunar \u00ed faglegum tilgangi \u00ed st\u00fdr\u00f0um ranns\u00f3knarumhverfum.<\/p><\/blockquote>","protected":false},"excerpt":{"rendered":"

        Eiginleikar 4-HO-MPT f\u00famarat<\/span><\/span><\/h3>\n

        Samheiti:<\/span><\/span><\/strong> 4-h\u00fddrox\u00fd-N-met\u00fdl-N-pr\u00f3p\u00fdltryptam\u00edn f\u00famarat <\/span><\/span>
        \nCAS-n\u00famer:<\/span><\/span><\/strong> 763035-03-6 <\/span><\/span>
        \nForm\u00fala:<\/span><\/span><\/strong> 3-(2-(met\u00fdl(pr\u00f3p\u00fdl)am\u00edn\u00f3)et\u00fdl)-1H-ind\u00f3l-4-\u00f3l f\u00famarat <\/span><\/span>
        \nM\u00f3lmassi:<\/span><\/span><\/strong> 348,4 g\/m\u00f3l <\/span><\/span>
        \nHreinleiki:<\/span><\/span><\/strong> >97%<\/span><\/span><\/p>","protected":false},"featured_media":28958,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[544,381],"product_tag":[326],"class_list":{"0":"post-23476","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-4-ho-mpt","7":"product_cat-tryptamines","8":"product_tag-nl","10":"first","11":"instock","12":"taxable","13":"shipping-taxable","14":"purchasable","15":"product-type-variable"},"_links":{"self":[{"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product\/23476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/comments?post=23476"}],"version-history":[{"count":2,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product\/23476\/revisions"}],"predecessor-version":[{"id":26620,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product\/23476\/revisions\/26620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/media\/28958"}],"wp:attachment":[{"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/media?parent=23476"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product_brand?post=23476"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product_cat?post=23476"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/researchchemicallab.eu\/is\/wp-json\/wp\/v2\/product_tag?post=23476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}